Clinical trial
A Randomised Controlled Trial Comparing the Effect of the Faster-acting Insulin Analog - Insulin Fiasp® - Versus Insulin Novorapid® in the Treatment of Women With Type 1 or Type 2 Diabetes During Pregnancy and Lactation. The Copen-fast Trial
NCT03770767 is registered in ClinicalTrials.gov with Rigshospitalet, Denmark as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised Controlled Trial Comparing the Effect of the Faster-acting Insulin Analog - Insulin Fiasp® - Versus Insulin Novorapid® in the Treatment of Women With Type 1 or Type 2 Diabetes During Pregnancy and Lactation. The Copen-fast Trial
- Lead sponsor
- Rigshospitalet, Denmark
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 11, 2019
- Completion date
- March 23, 2023
- Enrollment
- 216 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.